Dentaltech startup Biolux Technology raises €4.26m to accelerate othodontics innovation

Dentaltech startup Biolux Technology, a player in advanced light-accelerated orthodontics, has raised €4.26 million seed funding from European VC redalpine and Revere Partners, the only venture capital fund focused on oral health.

Biolux will use the funds to launch a smart digital platform for its flagship product, OrthoPulse®, offering real-time monitoring and treatment optimization for both orthodontists and patients. This will further OrthoPulse®’s mission to enhance orthodontic treatments through cutting-edge technology and research-driven innovations. In 2023, orthodontic market valued at $9 billion (12 million cases) and expected to grow at 15% CAGR to reach $21 billion by 2030 (30 million cases).

Alongside these developments, Biolux Technology also announced the appointment of Raphael Pascaud as Chairman of the Board. Pascaud brings a wealth of leadership experience from his roles on various boards and executive positions in the dental industry, including at companies like DentalMonitoring and Align Technology. With his deep industry expertise, Pascaud will help in steering Biolux through its next phase of growth and innovation.

Marcel Pordes, CEO, Biolux Technology: "We are thrilled to partner with both redalpine and Revere Partners, and welcome Raphael Pascaud as our Chairman. This investment, along with our new digital platform for OrthoPulse®, represents a critical milestone in our journey to revolutionize orthodontics. We are committed to providing patients with faster, more efficient treatment options, and ensuring orthodontists have the tools they need to deliver exceptional care."

Daniel Dillinger, Principal, redalpine: ''Biolux is already transforming orthodontics and delivering exceptional patient outcomes with its FDA-cleared, patented, and commercially successful flagship product, OrthoPulse®. We’re delighted to partner with the Biolux team as they enter the next phase of growth, further enhancing the state-of-the-art user experience to support their rapid scaling and expansion in the U.S. market.''

The next-generation OrthoPulse® features an exclusive, patented light-accelerated technology and an exceptionally low failure rate for more reliable treatment. Using safe near-infrared light therapy, OrthoPulse® accelerates tooth movement, cutting treatment times by up to 50%. This game-changing approach not only shortens the orthodontic process but also tackles a critical issue in patient care - longer treatments often lead to reduced compliance and more expensive, time-consuming refinements.

With this new funding, Biolux Technology will accelerate the development of OrthoPulse®, advance clinical research, and develop innovative solutions that improve patient outcomes and revolutionize orthodontic treatment worldwide.

www.orthopulse.com

Follow Marketing Report on LinkedIn